This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TAGLN2 / Transgelin-2 · Western blot design guide
Design a Western Blot for TAGLN2
Source-linked TAGLN2 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-TAGLN2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
TAGLN2 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~22.4 kDa | |
| Gel | 12–15% (standard starting point) | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Acetylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 2 isoform(s) |
Section 1
Source-Linked TAGLN2 Western Blot Protocol Options
The A05012 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | Target-positive lysate and matched negative control (standard starting point) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Short semi-dry transfer; verify retention (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A05012; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected TAGLN2 Western Blot Band Size?
TAGLN2 is predicted at 22.4 kDa; isoforms and modifications are annotated, but their effects on band migration are unproven.
| Band near 22.4 kDa | Consistent with the predicted TAGLN2 mass; confirm identity with a control. |
| Two bands near the expected region | Could reflect isoforms 1 and 2, whose separate migration is unproven. |
| One band despite two annotated isoforms | Isoforms 1 and 2 may not resolve as separate bands. |
| Band shifted from 22.4 kDa | Annotated modifications may affect migration, but no shift is established. |
💡Expected TAGLN2 appearanceTAGLN2 has a predicted mass of 22.4 kDa and no supplied empirical band; verify any band near that size with an identity control because isoform migration and modification effects are unestablished.
| Predicted TAGLN2 mass | Provides a 22.4 kDa reference, not a measured band position. |
| Splice isoform 1 | Its individual mass and migration are not supplied. |
| Splice isoform 2 | Its size relative to isoform 1 is not supplied. |
| Alternative splicing into isoforms 1 and 2 | Could affect band position, but separate bands are not established. |
| Situation | Likely cause | Next action |
|---|---|---|
| Band higher than expected | TAGLN2 has annotated modifications, but their effect on migration is unestablished. | Compare with a TAGLN2 knockdown control before assigning the band. |
| Band lower than expected | An isoform is possible, but individual isoform masses are unavailable. | Check band identity with TAGLN2 knockdown and an isoform-specific control. |
| Broad smear instead of sharp band | The listed phosphorylation and other modifications do not establish a smear. | Check sample integrity and confirm TAGLN2-specific signal with a knockdown control. |
| Multiple bands | Isoforms 1 and 2 are annotated, but distinct migration is unproven. | Compare isoform-specific controls and TAGLN2 knockdown. |
| Fragments below expected size | Sample degradation is possible; no cleavage feature is supplied. | Prepare fresh samples with protease inhibitors and check which bands disappear after TAGLN2 knockdown. |
Experiment evidence
Western blot images showing TAGLN2 band
A05012 · TAGLN2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for TAGLN2 Western blot
🧪For positive controls for TAGLN2 in Western blot, you can use no HPA-supported tissue or cell line from the supplied data because no positive candidates are listed.
Positive control: No high/medium HPA tissue identified
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: A positive control cannot be selected from these data; adipose tissue is listed as not detected.
HPA tissue expression evidence for TAGLN2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No high/medium HPA tissues identified in the supplied evidence. | ||||
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| No lower-expression tissue rows available in the supplied evidence. | ||||
Section 3
Advanced TAGLN2 Western Blot Tips
Deeper troubleshooting and optimisation questions for TAGLN2, answered from its protein features.
Where should the main TAGLN2 band appear?
Band shift · The canonical protein has a predicted mass of 22.4 kDa. Use that as a reference when examining the blot; no observed band position is supplied. The listed modifications alone do not establish a visible shift or explain a difference between apparent and predicted mass.
Could TAGLN2 isoforms produce different bands?
Isoforms · UniProt lists isoforms 1 and 2. In isoform 2, the initial M is replaced by MSAFSLALALVSSPQPPPPIGM, changing the N terminus and sequence length. Check which isoform your antibody recognizes before assigning separate bands; the supplied features do not establish their apparent positions.
Yes. Isoform 2 has an alternative N terminus, so an antibody against that region may recognize the isoforms differently. Check the immunogen sequence against both isoforms before interpreting a missing or additional band.
Yes. Isoform 2 has an alternative N terminus, so an antibody against that region may recognize the isoforms differently. Check the immunogen sequence against both isoforms before interpreting a missing or additional band.
Which TAGLN2 modifications matter when interpreting bands?
PTM · UniProt lists N-acetylalanine at position 2; phosphoserine at 11 and 163; N6-acetyllysine at 17 and 20; phosphothreonine at 180; and omega-N-methylarginine at 182 and 196. These are UniProt coordinates, which may differ from paper or antibody numbering. Their presence does not establish a visible band shift.
If measuring phosphorylation, identify whether the antibody targets UniProt phosphoserine 11 or 163, or phosphothreonine 180. Report the site and coordinate convention, and compare its signal with a total-TAGLN2 measurement. The listed sites do not indicate how much of the protein is phosphorylated in a sample.
If measuring phosphorylation, identify whether the antibody targets UniProt phosphoserine 11 or 163, or phosphothreonine 180. Report the site and coordinate convention, and compare its signal with a total-TAGLN2 measurement. The listed sites do not indicate how much of the protein is phosphorylated in a sample.
Does this guide establish induction of TAGLN2?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for TAGLN2?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A05012 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should TAGLN2 be quantified?
Quantitation · Standard workflow guidance: quantify only a validated target band within the linear exposure range. Use consistent sample preparation and loading, retain biological replicates, and avoid interpreting saturation or loading differences as regulation.
How should unexpected higher TAGLN2 bands be interpreted?
Interpretation · Consider isoform recognition and antibody specificity before assigning a higher band. UniProt lists Ubl conjugation and an isopeptide bond as keywords, but supplies no conjugation site or observed band pattern. The features alone cannot identify a higher band as modified TAGLN2.
Boster reagents
TAGLN2 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-Transgelin-2 TAGLN2 Antibody
Cat # A05012
the supplier A05012 is an anti-TAGLN2 polyclonal antibody listed for Western blot, with reported human and mouse reactivity. A WB image is available, but the supplied evidence does not specify the tested samples or conditions.
Which to pick: A05012 is the only listed TAGLN2 antibody. It has a WB image and reported human and mouse reactivity; check the image and product details for relevance to your sample and conditions.
Source: BosterBio TAGLN2 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry P37802.
- Human Protein Atlas. TAGLN2 tissue expression.
- PMC6324682 — target-verified WB comparison
- PMC12212467 — target-verified WB comparison
- PMC6215889 — target-verified WB comparison